AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01061853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOPICAL BETAMETHASONE 0.05%
Description: APPLICATION ON THE LESIONS OF TOPICAL BETAMETHASONE (DIPROLENE\*)0.05% bid during 3 months
Study NCT01661530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E enhanced soup
Description: vitamin E enhancement is by virtue of the natural vitamin E content of the food ingredients
Study NCT01661530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-enhanced soups
Description: Similar looking and tasting soups with low vitamin E content by virtue of food ingredients
Study NCT00141713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Patients enrolled on the study will receive etanercept at 0.4 mg/kg per dose up to a maximum of 25 mg per dose subcutaneously twice a week. Etanercept must be initiated within 72 hours of starting solumedrol.
Study NCT02648113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion
Description: Transfusions are withheld unless Hb is \<= 8 g/dL, with a target Hb of 8 to 10 g /dL
Study NCT02648113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liberal transfusion
Description: transfusions are allowed as soon as Hb \<= 10 g/dL with a target of 11 g /dL
Study NCT02648113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: red blood transfusion
Study NCT02651883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening invitation (with education)
Description: The participant will be provided with brief education about the importance and effectiveness of cervical cancer screening, and invited to schedule an appointment for a free in-clinic screening
Study NCT02651883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening invitation (with education)
Description: The participant will be provided with brief education about the importance and effectiveness of cervical cancer screening, and invited to schedule an appointment for a free in-clinic screening
Study NCT02651883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-collection for HPV testing
Description: Participant is provided with a kit to take a self-collected sample at home and return it by mail for HPV testing. Results are provided to participant by phone.
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO1507
Description: 27mg/kg iv, monotherapy
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: as prescribed
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: as prescribed
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: as prescribed
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: as prescribed
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: as prescribed
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: as prescribed
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: as prescribed
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: as prescribed
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: as prescribed
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: as prescribed
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: as prescribed
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexel
Description: as prescribed
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: as prescribed
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: as prescribed
Study NCT00811993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: as prescribed
Study NCT00006341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implant
Description: A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
Study NCT04051099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with 0.25% bupivacaine 8 ml each (total 16 ml)
Description: bilateral superficial cervical plexus
Study NCT04051099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus propofol infusion
Description: Dexmedetomidine 0.5 ug/kg infusion in 10 min then 0.5 ug/kg/h, Propofol infusion
Study NCT04051099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local infiltraion analgesia
Description: local infiltration analgesia with 2%lidocaine with adrenaline 5 ug/ml 10 ml
Study NCT04051099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia with endotracheal tube
Description: Induction with Propofol and intubation with cisatracurium
Study NCT02009059 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive temperature in hypothermia
Description: accuracy of non-invasive temperature measurement in deep hypothermia compared to core temperature
Study NCT03806023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hand movements (signals from thumb muscle) triggered PNS and TMS
Description: PNS, TMS or PNS+TMS will be delivered while the participant performs specific finger tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function.
Study NCT02176083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message management prompts
Study NCT02176460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.5mg twice daily for 16 weeks
Study NCT02176460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet twice daily
Study NCT04267185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Together for PwMS and their CGs (PAT-MS)
Description: A dyadic physical activity intervention approach for PwMS and their family CGs affected by moderate-to-severe MS disability.
Study NCT02615392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Park Prescription
Description: Please refer to the information included in the arm description.
Study NCT03213197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPR video
Description: Patient watches a short CPR video
Study NCT02912455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: canagliflozin
Description: encapsulated (gelatin capsule).
Study NCT02912455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for canagliflozin)
Description: encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.
Study NCT01934127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N1 vaccine GSK2789869A
Description: One dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while second dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
Study NCT01934127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N1 vaccine GSK2789868A
Description: One dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
Study NCT01934127 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of placebo administered intramuscularly at the deltoid region of the dominant arm at Day 21
Study NCT01542905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Description: Korean Red Ginseng Capsule (1g/day) for 8 Weeks
Study NCT01542905 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule (1g/day) for 8 Weeks
Study NCT01982838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural de novo
Description: Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
Study NCT01982838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSE
Description: The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
Study NCT01746108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix™
Description: 1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
Study NCT03982940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BGP+ Stent Graft System as bridging stent
Description: BGP+ Stent Graft System as bridging stent
Study NCT00395642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kronos LV-T, Lumax HF-T
Description: Implanted CRT-device sends out device diagnostics (e.g. heart rate, device and lead integrity, patient activity) via CardioMessenger on daily basis. In addition, daily weight and blood pressure readings are taken; remote data are analyzed by investigational sites via the internet on a weekly basis.
Study NCT00096993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided as a single-use formulation for infusion.
Study NCT00096993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was provided as a solution for infusion.
Study NCT00096993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was provided as a solution for infusion.
Study NCT00096993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab was provided as a single-use formulation for infusion.
Study NCT02164032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal insulin administration
Description: intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
Study NCT02164032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Dilution Buffer (Novo Nordisk)
Description: intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
Study NCT02164032 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 1H magnetic resonance spectroscopy
Description: 1H MR spectroscopy and imaging will be performed on the on on the 3.0-T Tim Trio System (Siemens Erlangen Germany). MR Spectroscopy and imaging measurements will last no more than 90 minutes all together.
Study NCT02164032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1H magnetic resonance spectroscopy
Description: 1H MR spectroscopy and imaging will be performed on the on on the 3.0-T Tim Trio System (Siemens Erlangen Germany). MR Spectroscopy and imaging measurements will last no more than 90 minutes all together.
Study NCT03092336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: electrical stimulation training
Study NCT03092336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: strength training group
Study NCT00886925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Albumin 20%. Day 0: 400-600 ml. Day 2: 200-400 ml.
Study NCT00886925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Day 0: 400-600 ml. Day 2: 200-400 ml.
Study NCT01291134 — intervention group
Intervention type: BIOLOGICAL
Intervention: PureGen Osteoprogenitor Cell Allograft
Description: PureGen Osteoprogenitor Cell Allograft.
Study NCT01746108 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: 1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
Study NCT01328808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/APAP
Description: In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute
Study NCT00772655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab
Description: A single course of 90Y-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111In-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 \[if platelets are below 150000/µl only 11 MBq/kg are administered).
Study NCT00772655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
Study NCT00563745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedicine program
Description: One year TM with continuous (h 24) on call accessibility to a nurse and/or a pulmonologist, a web-based call centre and a pulse oxymetry tracing will be provided.
Study NCT02604485 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cohort 1
Description: XOMA 358 single dose level A administered by an intravenous infusion
Study NCT02604485 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cohort 2
Description: XOMA 358 single dose level B administered by an intravenous infusion
Study NCT02604485 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cohort 3
Description: XOMA 358 single dose level C administered by an intravenous infusion
Study NCT02604485 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cohort 4
Description: XOMA 358 single dose level D administered by an intravenous infusion
Study NCT06433440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVRV
Description: Group-1 will receive PVRV ID on on the following days: Day0, Day3, Day7, while group-2 will receive PVRV IM on Day0, Day3, Day7, Day14, and Day28.
Study NCT01075399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F 18]HX4
Description: Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy, will be imaged under PET/CT with \[F 18\]HX4
Study NCT02267213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipotecan
Description: Administer 40mg Lipotecan at D1, D8, D15 of each cycle.
Study NCT04353388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CBC-DIFF Monocyte Volume Width Distribution (MDW)
Description: MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
Study NCT01329588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monthly antibiotic
Description: Azithromycin 1g per os once at months 1, 4 and 7 Ciprofloxacin 500 mg per os once at months 2, 3, 5, 6, 8 and 9
Study NCT03378778 — intervention group
Intervention type: PROCEDURE
Intervention: Root canal treatment
Description: Root Canal Treatment followed by Ceramic Onlay restoration
Study NCT00848068 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FID 114657
Description: artificial tears
Study NCT00848068 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: OPTIVE Lubricant Eye Drops
Description: artificial tears
Study NCT02223013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBV 308 SE solution
Study NCT02223013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBV 308 SE capsule L
Study NCT02223013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBV 308 SE capsule S
Study NCT02880332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: During usual care therapy, children and their parents will receive a +/- 1 h session containing bio-medical directed education and information about the gastro-intestinal system and its function. This knowledge will be brought to bear with a hypnotic journey through their body, guided by a nurse with specific expertise in pediatric abdominal pain. Furthermore, the influence of stress on the gastro-intestinal system will be explained, combined with exercises to practise abdominal respiration.
Study NCT02880332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: During usual care therapy, children and their parents will receive a +/- 1 h session containing bio-medical directed education and information about the gastro-intestinal system and its function. This knowledge will be brought to bear with a hypnotic journey through their body, guided by a nurse with specific expertise in pediatric abdominal pain. Furthermore, the influence of stress on the gastro-intestinal system will be explained, combined with exercises to practise abdominal respiration.
Study NCT02880332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience education
Description: This therapy will consist out of a +/- 1 h one-on-one educational session about neurophysiology of pain, adjusted to the child's comprehension status. The content of the education sessions and pictures will be based on the book Explain Pain by Butler and Moseley and will include explanation and reassurance about the cause of pain, a brief summary of relevant pain mechanisms and the integral role of psychosocial and physical factors in precipitating and maintaining pain. Metaphors, leaflets, books and audio-visual media will be used in a supportive function to consolidate verbally transmitted information. Parents will participate in the PNE session as well.
Study NCT02880332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extra care
Description: During this therapy session, all the patient's/ parents questions that arose from the previous session (Usual care) will be answered. Afterwards, the educated content from this previous session will be revised. Nothing new will be taught. At the end of the session, the participant will be asked to demonstrate the previously learned exercises on abdominal respiration. If the exercises are not well performed, the therapist will correct them.
Study NCT03109652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups. Oral TXA is given from postoperative day 1 only to experimental groups. Duration of oral TXA administration is different between two experimental groups. (5 days in IV TXA and Oral TXA 5 days group and 2 days in IV TXA and Oral TXA 2 days group)
Study NCT03109652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups. Oral TXA is given from postoperative day 1 only to experimental groups. Duration of oral TXA administration is different between two experimental groups. (5 days in IV TXA and Oral TXA 5 days group and 2 days in IV TXA and Oral TXA 2 days group)
Study NCT00637832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00637832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00637832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride